Table 5.
Characteristics of metastatic colorectal cancer patients by commonly administered treatment sequences
| Characteristics | Treatment sequences | ||||
|---|---|---|---|---|---|
| OI-OIB-TB (N = 275) | OIB-OIB-TB (N = 199) | OI-OIB (N = 178) | OIB-OIB (N = 169) | P value | |
| Age (years) | 0.0600 | ||||
| 65–69 | 108 (39.3) | 81 (40.7) | 56 (31.5) | 56 (33.1) | |
| 70–74 | 84 (30.6) | 72 (36.2) | 57 (32.0) | 49 (29.0) | |
| 75–79 | 56 (20.4) | 32 (16.1) | 47 (26.4) | 38 (22.5) | |
| ≥80 | 27 (9.8) | 14 (7.0) | 18 (10.1) | 26 (15.4) | |
| Race/ethnicity | 0.4093 | ||||
| Caucasian | 235 (85.5) | 173 (86.9) | 144 (80.9) | 142 (84.0) | |
| Other | 40 (14.6) | 26 (13.1) | 34 (19.1) | 27 (16.0) | |
| Sex | 0.1751 | ||||
| Male | 161 (58.6) | 113 (56.8) | 86 (48.3) | 91 (53.9) | |
| Female | 114 (41.5) | 86 (43.2) | 92 (51.7) | 78 (46.2) | |
| Marital status | 0.2983 | ||||
| Married | 189 (68.7) | 125 (62.8) | 114 (64.0) | 102 (60.4) | |
| Unmarried/unknown | 86 (31.3) | 74 (37.2) | 64 (36.0) | 67 (39.6) | |
| Tumor grade | 0.7064 | ||||
| Well/moderately differentiated | 176 (64.0) | 121 (60.8) | 105 (59.0) | 107 (63.3) | |
| Poorly/undifferentiated/unknown | 99 (36.0) | 78 (39.2) | 73 (41.0) | 62 (36.7) | |
| Comorbidity scores | 0.0129* | ||||
| 0 | 173 (62.9) | 123 (61.8) | 84 (47.2) | 97 (57.4) | |
| 1 | 71 (25.8) | 49 (24.6) | 69 (38.8) | 44 (26.0) | |
| ≥2 | 31 (11.3) | 27 (13.6) | 25 (14.0) | 28 (16.6) | |
| Metastasis | |||||
| Liver | 206 (74.9) | 143 (71.9) | 126 (70.8) | 128 (75.7) | 0.6458 |
| Lung | 41 (14.9) | 31 (15.6) | 22 (12.4) | 26 (15.4) | 0.8079 |
| Abdomen | 57 (20.7) | 37 (18.6) | 31 (17.4) | 25 (14.8) | 0.4608 |
| Other | 43 (15.6) | 19 (9.6) | 34 (19.1) | 18 (10.7) | 0.0248* |
| Unknown | 37 (13.5) | 29 (14.6) | 31 (17.4) | 24 (14.2) | 0.7010 |
| Cancer site | 0.0829 | ||||
| Colon | 194 (70.6) | 155 (77.9) | 128 (71.9) | 135 (79.9) | |
| Rectal | 81 (29.5) | 44 (22.1) | 50 (28.1) | 34 (20.1) | |
| SES (poverty) | 0.2732 | ||||
| 1st (low SES) | 62 (22.6) | 41 (20.6) | 34 (19.1) | 41 (24.3) | |
| 2nd | 56 (20.4) | 53 (26.6) | 48 (27.0) | 37 (21.9) | |
| 3rd | 69 (25.1) | 53 (26.6) | 43 (24.2) | 54 (32.0) | |
| 4th (high SES) | 88 (32.0) | 52 (26.1) | 53 (29.8) | 37 (21.9) | |
| Region | 0.0915 | ||||
| Midwest | 31 (11.3) | 18 (9.1) | 20 (11.2) | 15 (8.9) | |
| North east | 55 (20.0) | 41 (20.6) | 38 (21.4) | 36 (21.3) | |
| South | 45 (16.4) | 45 (22.6) | 49 (27.5) | 48 (28.4) | |
| West | 144 (52.4) | 95 (47.7) | 71 (39.9) | 70 (41.4) | |
| Urban/rural | 0.1894 | ||||
| Less urban/rural | 22 (8.0) | 18 (9.1) | 19 (10.7) | 24 (14.2) | |
| Metro/urban | 253 (92.0) | 181 (91.0) | 159 (89.3) | 145 (85.8) | |
| Year of diagnosis | <0.0001* | ||||
| 2004–2005 | 109 (39.6) | 52 (26.1) | 56 (31.5) | 40 (23.7) | |
| 2006–2007 | 90 (32.7) | 95 (47.7) | 48 (27.0) | 56 (33.1) | |
| 2008–2009 | 76 (27.6) | 52 (26.1) | 74 (41.6) | 73 (43.2) | |
Data are presented as n (%) unless otherwise indicated
OI-OIB first-line oxaliplatin or irinotecan followed by second-line oxaliplatin or irinotecan + bevacizumab, OIB-OIB first-line oxaliplatin or irinotecan + bevacizumab followed by second-line oxaliplatin or irinotecan + bevacizumab, OI-OIB-TB OI-OIB followed by a third-line targeted biologic, OIB-OIB-TB OIB-OIB followed by a third-line targeted biologic, SES socio-economic status
* Significant at α = 0.05